Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-78c5997874-m6dg7 Total loading time: 0 Render date: 2024-11-11T02:32:37.233Z Has data issue: false hasContentIssue false

Chapter 17 - Does Cannabis Cause Psychosis?

The Epidemiological Evidence

from Part VI - Cannabinoids and Schizophrenia: Aetiopathology and Treatment Implications

Published online by Cambridge University Press:  12 May 2023

By
Emmet Power ,
Colm Healy ,
Robin M. Murray  and
Mary Cannon
Edited by
Deepak Cyril D'Souza ,
David Castle  and
Sir Robin Murray
Deepak Cyril D'Souza
Affiliation:
Staff Psychiatrist, VA Connecticut Healthcare System; Professor of Psychiatry, Yale University School of Medicine
David Castle
Affiliation:
University of Tasmania, Australia
Sir Robin Murray
Affiliation:
Honorary Consultant Psychiatrist, Psychosis Service at the South London and Maudsley NHS Trust; Professor of Psychiatric Research at the Institute of Psychiatry
Get access

Summary

In this chapter, we discuss whether there is a causal relationship between cannabis use and psychosis in terms of the criteria of causality proposed by Bradford-Hill. We conclude that the evidence for each of the criteria ranges from consistent in the context of strength, consistency, and temporality; strong in the context of biological gradient and experimental evidence; plausible in the context of biological plausibility and coherence. The association is not specific for psychosis but also includes depression and suicidal thoughts, and it is unclear whether the analogy criteira are appropriate. Thus, the epidemiological, experimental, and genetic evidence suggests that cannabis, particularly high potency cannabis, is a contributing factor to the incidence of psychosis in the population. In consequence, over the last 20 years there has been a shift in the argument from ‘whether there is a causal relationship between cannabis and psychosis’ to considering the magnitude of this relationship.

Keywords

cannabiscannabinoidsepidemiologycausationBradford-Hillconsistencytemporalitybiological gradientexperimental evidenceplausibility and coherence
Type
Chapter
Information
Marijuana and Madness , pp. 167 - 177
Publisher: Cambridge University Press
Print publication year: 2023

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Allebeck, P., Adamsson, C., Engström, A., et al. (1993). Cannabis and schizophrenia: A longitudinal study of cases treated in Stockholm County. Acta Psychiatr Scand, 88, 21–24.Google Scholar
Andréasson, S., Engström, A., Allebeck, P., et al. (1987). Cannabis and schizophrenia: A longitudinal study of Swedish conscripts. Lancet, 330, 1483–1486.CrossRefGoogle Scholar
Arango, C., Dragioti, E., Solmi, M., et al. (2021). Risk and protective factors for mental disorders beyond genetics: An evidence‐based atlas. World Psychiatry, 20, 417–436.CrossRefGoogle ScholarPubMed
Arseneault, L., Cannon, M., Witton, J., et al. (2004). Causal association between cannabis and psychosis: Examination of the evidence. Br J Psychiatry, 184, 110–117.Google Scholar
Ayonrinde, O. A. (2020). Cannabis and psychosis: Revisiting a nineteenth century study of ‘Indian Hemp and Insanity’ in Colonial British India. Psychol Med, 50, 1164–1172.Google Scholar
Bechtold, J., Hipwell, A., Lewis, D. A., et al. (2016). Concurrent and sustained cumulative effects of adolescent marijuana use on subclinical psychotic symptoms. Am J Psychiatry, 173, 781–789.Google Scholar
Belbasis, L., Köhler, C. A., Stefanis, N., et al. (2018). Risk factors and peripheral biomarkers for schizophrenia spectrum disorders: An umbrella review of meta‐analyses. Acta Psychiatr Scand, 137, 88–97.Google Scholar
Carliner, H., Brown, Q. L., Sarvet, A. L., et al. (2017). Cannabis use, attitudes, and legal status in the US: A review. Prev Med, 104, 13–23.CrossRefGoogle ScholarPubMed
Caspi, A., Houts, R. M., Ambler, A., et al. (2020). Longitudinal assessment of mental health disorders and comorbidities across 4 decades among participants in the Dunedin birth cohort study. JAMA Netw Open, 3, e203221.Google Scholar
Clark, C. S. (2019). High-potency cannabis and incident psychosis: Correcting the causal assumption. Lancet Psychiatry, 6, e14.CrossRefGoogle ScholarPubMed
Clouston, T. S. (1896). The Cairo Asylum: Dr. Warnock on hasheesh insanity. J Mental Sci, 42, 790–795.Google Scholar
D’Souza, D. C., Abi-Saab, W. M., Madonick, S., et al. (2005). Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction. Biol Psychiatry, 57, 594–608.Google Scholar
Davis, G. P., Compton, M. T., Wang, S., et al. (2013). Association between cannabis use, psychosis, and schizotypal personality disorder: Findings from the National Epidemiologic Survey on Alcohol and Related Conditions. Schizophr Res, 151, 197–202.Google Scholar
De Pablo, G. S., Catalan, A., and Fusar-Poli, P. (2020). Clinical validity of DSM-5 attenuated psychosis syndrome: Advances in diagnosis, prognosis, and treatment. JAMA Psychiatry, 77, 311–320.CrossRefGoogle Scholar
Di Forti, M., Marconi, A., Carra, E., et al. (2015). Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: A case-control study. Lancet Psychiatry, 2, 233–238.Google Scholar
Di Forti, M., Morgan, C., Dazzan, P., et al. (2009). High-potency cannabis and the risk of psychosis. Br J Psychiatry, 195, 488–491.Google Scholar
Di Forti, M., Morgan, C., Selten, J. P., et al. (2019a). High-potency cannabis and incident psychosis: Correcting the causal assumption – authors’ reply. Lancet Psychiatry, 6, 466–467.Google Scholar
Di Forti, M., Quattrone, D., Freeman, T. P., et al. (2019b). The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): A multicentre case-control study. Lancet Psychiatry, 6, 427–436.Google Scholar
European Monitoring Centre for Drugs and Drug Addiction. (2018). European Drug Report 2018: Trends and Developments. Luxembourg: Office for Official Publications of the European Communities.Google Scholar
Gage, S. H., Jones, H. J., Burgess, S., et al. (2017). Assessing causality in associations between cannabis use and schizophrenia risk: A two-sample Mendelian randomization study. Psychol Med, 47, 971–980.CrossRefGoogle Scholar
Gillespie, N. A., and Kendler, K. S. (2021). Use of genetically informed methods to clarify the nature of the association between cannabis use and risk for schizophrenia. JAMA Psychiatry, 78, 467–468.Google Scholar
Gillespie, N. A., Pasman, J. A., Treur, J. L., et al. (2019). High-potency cannabis and incident psychosis: Correcting the causal assumption. Lancet Psychiatry, 6, 464.Google Scholar
Giordano, G. N., Ohlsson, H., Sundquist, K., et al. (2015). The association between cannabis abuse and subsequent schizophrenia: A Swedish national co-relative control study. Psychol Med, 45, 407–414.Google Scholar
Gobbi, G., Atkin, T., Zytynski, T., et al. (2019). Association of cannabis use in adolescence and risk of depression, anxiety, and suicidality in young adulthood: A systematic review and meta-analysis. JAMA Psychiatry, 76, 426–434.Google Scholar
Guloksuz, S., Pries, L. K., Ten Have, M., et al. (2020). Association of preceding psychosis risk states and non‐psychotic mental disorders with incidence of clinical psychosis in the general population: A prospective study in the NEMESIS‐2 cohort. World Psychiatry, 19, 199–205.Google Scholar
Gunasekera, B., Davies, C., Martin-Santos, R., et al. (2021). The yin and yang of cannabis: A systematic review of human neuroimaging evidence of the differential effects of Δ9-tetrahydrocannabinol and cannabidiol. Biol Psychiatry Cogn Neurosci Neuroimaging, 6, 636–645.Google ScholarPubMed
Hall, W. (2019). The Indian Hemp Drugs Commission 1893–1894. Addiction, 114, 1679–1682.Google Scholar
Harley, M., Kelleher, I., Clarke, M., et al. (2010). Cannabis use and childhood trauma interact additively to increase the risk of psychotic symptoms in adolescence. Psychol Med, 40, 1627–1634.Google Scholar
Hill, A. B. (1965). The environment and disease: Association or causation? Proc R Soc Med. 58, 295–300.Google Scholar
Hindley, G., Beck, K., Borgan, F., et al. (2020). Psychiatric symptoms caused by cannabis constituents: A systematic review and meta-analysis. Lancet Psychiatry, 7, 344–353.Google Scholar
Hjorthøj, C., Posselt, C. M., and Nordentoft, M. (2021a). Development over time of the population-attributable risk fraction for cannabis use disorder in schizophrenia in Denmark. JAMA Psychiatry, 78, 1013–1019.Google Scholar
Hjorthøj, C., Uddin, M. J., Wimberley, T., et al. (2021b). No evidence of associations between genetic liability for schizophrenia and development of cannabis use disorder. Psychol Med, 51, 479–484.Google Scholar
Ioannidis, J. P. (2016). Exposure‐wide epidemiology: Revisiting Bradford Hill. Stat Med, 35, 1749–1762.Google Scholar
Jones, H. J., Gage, S. H., Heron, J., et al. (2018). Association of combined patterns of tobacco and cannabis use in adolescence with psychotic experiences. JAMA Psychiatry, 75, 240–246.Google Scholar
Jongsma, H. E., Gayer-Anderson, C., Lasalvia, A., et al. (2018). Treated incidence of psychotic disorders in the multinational EU-GEI study. JAMA Psychiatry, 75, 36–46.Google Scholar
Kendler, K. S., Ohlsson, H., Sundquist, J., et al. (2019). Prediction of onset of substance-induced psychotic disorder and its progression to schizophrenia in a Swedish national sample. Am J Psychiatry, 176, 711–719.Google Scholar
Konings, M., Stefanis, N., Kuepper, R., et al. (2012). Replication in two independent population-based samples that childhood maltreatment and cannabis use synergistically impact on psychosis risk. Psychol Med, 42, 149–159.Google Scholar
Koskinen, J., Löhönen, J., Koponen, H., et al. (2010). Rate of cannabis use disorders in clinical samples of patients with schizophrenia: A meta-analysis. Schizophr Bull, 36, 1115–1130.Google Scholar
Large, M., Sharma, S., Compton, M. T., et al. (2011). Cannabis use and earlier onset of psychosis: A systematic meta-analysis. Arch Gen Psychiatry, 68, 555–561.Google Scholar
Laviolette, S. R. (2021). Exploring the impact of adolescent exposure to cannabinoids and nicotine on psychiatric risk: Insights from translational animal models. Psychol Med, 51, 940–947.CrossRefGoogle ScholarPubMed
Lee, P. N., Forey, B. A., and Coombs, K. J. (2012). Systematic review with meta-analysis of the epidemiological evidence in the 1900s relating smoking to lung cancer. BMC Cancer, 12, 1–90.CrossRefGoogle ScholarPubMed
Libuy, N., de Angel, V., Ibáñez, C., et al. (2018). The relative prevalence of schizophrenia among cannabis and cocaine users attending addiction services. Schizophr Res, 194, 13–17.Google Scholar
Linnman, C. (2019). High-potency cannabis and incident psychosis: Correcting the causal assumption. Lancet Psychiatry, 6, 465–466.Google Scholar
Linszen, D. H., Dingemans, P. M., and Lenior, M. E. (1994). Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry, 51, 273–279.Google Scholar
Marconi, A., Di Forti, M., Lewis, C. M., et al. (2016). Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophr Bull, 42, 1262–1269.Google Scholar
McGrath, J., Welham, J., Scott, J., et al. (2010). Association between cannabis use and psychosis-related outcomes using sibling pair analysis in a cohort of young adults. Arch Gen Psychiatry, 67, 440–447.Google Scholar
McGuire, P., Robson, P., Cubala, W. J., et al. (2018). Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: A multicenter randomized controlled trial. Am J Psychiatry, 175, 225–231.Google Scholar
Moore, T. H., Zammit, S., Lingford-Hughes, A., et al. (2007). Cannabis use and risk of psychotic or affective mental health outcomes: A systematic review. Lancet, 370, 319–328.CrossRefGoogle ScholarPubMed
Morrison, P. D., Zois, V., McKeown, D. A., et al. (2009). The acute effects of synthetic intravenous Δ9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol Med, 39, 1607–1616.CrossRefGoogle ScholarPubMed
Murray, R. M., Englund, A., Abi-Dargham, A., et al. (2017). Cannabis-associated psychosis: Neural substrate and clinical impact. Neuropharmacology, 124, 89–104.Google Scholar
Murray, R. M., and Hall, W. (2020). Will legalization and commercialization of cannabis use increase the incidence and prevalence of psychosis? JAMA Psychiatry, 77, 777–778.CrossRefGoogle ScholarPubMed
Mustonen, A., Niemelä, S., Nordström, T., et al. (2018). Adolescent cannabis use, baseline prodromal symptoms and the risk of psychosis. Br J Psychiatry, 212, 227–233.Google Scholar
Pasman, J. A., Verweij, K. J., Gerring, Z., et al. (2018). GWAS of lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits, and a causal effect of schizophrenia liability. Nature Neurosci, 21, 1161–1170.CrossRefGoogle Scholar
Plana-Ripoll, O., Pedersen, C. B., Holtz, Y., et al. (2019). Exploring comorbidity within mental disorders among a Danish national population. JAMA Psychiatry, 76, 259–270.Google Scholar
Quattrone, D., Ferraro, L., Tripoli, G., et al. (2021). Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: The EU-GEI case–control study. Psychol Med, 51, 1329–1337.Google Scholar
Radua, J., Ramella‐Cravaro, V., Ioannidis, J. P., et al. (2018). What causes psychosis? An umbrella review of risk and protective factors. World Psychiatry, 17, 49–66.Google Scholar
Rolfe, M., Tang, C. M., Sabally, S., et al. (1993). Psychosis and cannabis abuse in The Gambia: A case-control study. Br J Psychiatry, 163, 798–801.Google Scholar
Rothman, K. J., and Greenland, S. (1998). Types of epidemiologic studies. Mod Epidemiol, 3, 95–97.Google Scholar
Rubino, T., and Parolaro, D. (2016). The impact of exposure to cannabinoids in adolescence: Insights from animal models. Biol Psychiatry, 79, 578–585.Google Scholar
San-Martin, R., Castro, L. A., Menezes, P. R., et al. (2020). Meta-analysis of sensorimotor gating deficits in patients with schizophrenia evaluated by prepulse inhibition test. Schizophr Bull, 46, 1482–1497.Google Scholar
Semple, D. M., McIntosh, A. M., and Lawrie, S. M. (2005). Cannabis as a risk factor for psychosis: Systematic review. J Psychopharmacol, 19, 187–194.CrossRefGoogle ScholarPubMed
Sommer, I., and van den Brink, W. (2019). High-potency cannabis and incident psychosis: Correcting the causal assumption. Lancet Psychiatry, 6, 464–465.Google Scholar
Sullivan, P. F., Kendler, K. S., and Neale, M. C. (2003). Schizophrenia as a complex trait: Evidence from a meta-analysis of twin studies. Arch Gen psychiatry, 60, 1187–1192.Google Scholar
Susser, M. (1991). What is a cause and how do we know one? A grammar for pragmatic epidemiology. Am J Epidemiol, 133, 635–648.CrossRefGoogle Scholar
Thomsen, K. R., Lindholst, C., Thylstrup, B., et al. (2019). Changes in the composition of cannabis from 2000–2017 in Denmark: Analysis of confiscated samples of cannabis resin. Exp Clin Psychopharmacol, 27, 402.Google Scholar
Tsuang, M. T., Lyons, M. J., Eisen, S. A., et al. (1996). Genetic influences on abuse of illicit drugs: A study of 3,297 twin pairs. Am J Med Genet, 67, 473–477.Google Scholar
United Nations Office on Drugs and Crime (2006). World Drug Report (Vol. 1). Amsterdam: Boom Koninklijke Uitgevers.Google Scholar
Varese, F., Smeets, F., Drukker, M., et al. (2012). Childhood adversities increase the risk of psychosis: A meta-analysis of patient-control, prospective-and cross-sectional cohort studies. Schizophr Bull, 38, 661–671.Google Scholar
Vaucher, J., Keating, B. J., Lasserre, A. M., et al. (2018). Cannabis use and risk of schizophrenia: A Mendelian randomization study. Mol Psychiatry, 23, 1287–1292.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×